Treatment sequencing in metastatic castrate-resistant prostate cancer

@inproceedings{Sartor2014TreatmentSI,
  title={Treatment sequencing in metastatic castrate-resistant prostate cancer},
  author={Oliver A Sartor and Silke Gillessen},
  booktitle={Asian journal of andrology},
  year={2014}
}
Six different treatments have demonstrated improved survival in phase III trials targeted to patients with metastatic castration-resistant prostate cancer (mCRPC). Front-line therapeutic options for mCRPC include docetaxel, sipuleucel-T, abiraterone and radium-223. Post-docetaxel options include cabazitaxel, abiraterone, enzalutamide and radium-223. Despite much progress in recent years, much is yet unknown and debates occur over optimal treatment choices and sequences. None of the new agents… CONTINUE READING
Highly Cited
This paper has 26 citations. REVIEW CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 15 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 26 references

A retrospective study on cabazitaxel and abiraterone acetate sequential treatment (CAST) in docetaxel treated metastatic castrate‐resistant prostate cancer patients

  • MD Wissing, JLLM Coenen, P Van den Berg, IM Van Oort, R De Wit
  • Eur Cancer Congr
  • 2013

Similar Papers

Loading similar papers…